Symbols

AUTL

Autolus Therapeutics·NASDAQ

--(--)

AUTL fundamentals

AUTL Q4 2025 Earnings

Autolus Therapeutics (AUTL) released its earnings on Mar 27, 2026: revenue was 24.29M (YoY +83655.17%), beat estimates; EPS was -0.34 (YoY -277.78%), missed estimates.

Revenue / YoY

24.29M

+83655.17%

EPS / YoY

-0.34

-277.78%

Report date

Mar 27, 2026

AUTL Earnings Call Summary for Q4,2025

Revenue Growth: 2025 AUCATZYL revenue $74.3 million; 2026 guidance $120-135 million with >80 centers. Gross margins to turn positive in 2026.
Clinical Success: ROCCA real-world data shows 92% remission at day 28, matching clinical trial safety and efficacy.
Pipeline Momentum: CATULUS pediatric ALL Phase II, CARLYSLE lupus nephritis, and BOBCAT MS trials advancing; LUMINA pivotal study 2028 readout.
Financial Health: $300.7 million cash; 2026 operations funded. Accounting change aligns revenue/cost timing with second dose.

Earnings

EPS

Revenue

Revenue & Expenses

AUTL has released its 2025 Q4 earnings report, with revenue of 24.29M, reflecting a YoY change of 83655.17%, and net profit of -90.33M, showing a YoY change of -227.22%. The Sankey diagram below clearly presents AUTL's revenue sources and cost distribution.

Key Indicators

Autolus Therapeutics (AUTL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Autolus Therapeutics (AUTL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Autolus Therapeutics (AUTL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Autolus Therapeutics (AUTL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown